Fundraising Fox
/Companies
Sign in

Enlaza Therapeutics

San Diego, US · Founded 2020 · 68 employees on LinkedIn · 9 known investors

Find your way into Enlaza Therapeutics

312 people in our graph share verified history with the Enlaza Therapeutics team — schools, employers, funds. One of them is your warm intro.

Eben Massariunlockedknows Sergio G. Duron · together at Nerio Therapeutics (overlapped)
knows the team · via Nerio Therapeutics
knows the team · via Enlaza Therapeutics
knows the team · via COI Pharmaceuticals
×6knows the team · via Avalon BioVentures
×2knows the team · via The Scripps Research Institute

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.

BiotechDeep Tech

Founders & leadership

Enlaza Therapeutics was founded in 2020 by Sergio Duron and Sanford Madigan.

SDSergio Duron
Sergio DuronCo-Founder & Chief Executive OfficerManaging Partner at Avalon BioVentures
SMSanford Madigan
Sanford MadiganCo-Founder, President & Chief Business OfficerHe has over 30 years of experience in biotech leadership, including founding and serving as CEO of Nerio Therapeutics (acquired by Boehringer Ingelheim in 2024) and Calporta Therapeutics (acquired by Merck in 2019), as well as roles at Avalon Bioventures. Madigan holds a Ph.D. in genetics and B.S. in biochemistry from SUNY Stony Brook, and completed postdoctoral training at the Salk Institute for Biological Studies.
AH
Analeah HeidtChief Scientific Officer

Board

MMMarcos Milla
Marcos MillaBoard directorVenture Partner at Samsara BioCapital
JLJay Lichter
Jay LichterBoard directorManaging Partner at Avalon BioVentures
TRTighe Reardon
Tighe ReardonBoard directorInvestor at Avalon Ventures Management, Llc
JTJames Topper
James TopperBoard directorManaging Partner at Frazier Life Sciences
SSStephen Squinto
Stephen SquintoBoard directorVenture Partner at OrbiMed
SC
Shelley ChuBoard director

Investors · 9

Lightspeed Venture Partners✓ confirmed by Enlaza TherapeuticsMenlo Park · $1.7M – $87M

How we know: the company's own site · Lightspeed Venture Partners's portfolio page · funding news · Not right? Tell us

Samsara BioCapital✓ confirmed by Enlaza TherapeuticsMenlo Park

How we know: Samsara BioCapital's portfolio page · the company's own site · board seat on SEC Form D · funding news · Not right? Tell us

Avalon BioVentureslisted by Avalon BioVenturesLa Jolla

How we know: Avalon BioVentures's portfolio page · board seat on SEC Form D · Not right? Tell us

Pappas Capitallisted by Pappas CapitalDurham
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us

J.P. Morgan Asset Managementreported

How we know: funding news · Not right? Tell us

OrbiMedinferredNew York · $1M – $75Mvia Stephen Squinto · board

How we know: board seat on SEC Form D · Not right? Tell us

Also in the syndicate · 1

Life Sciences Group of J.P. Morgan Private Capitallead

Reported raises · per SEC filings

Form D private placements

$134.3M disclosed across 3 of 7 rounds · 2021–2025

▶$15MraisedSep 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Marcos MillaDirector
  • Stephen SquintoDirector
  • Tighe ReardonExecutive Officer
  • Jay LichterDirector
  • Shelley ChuDirector
  • Sergio DuronExecutive Officer, Director
  • James TopperDirector
  • Sanford MadiganExecutive Officer
Offering amount
$15M
Amount sold
$15M
First sale
Aug 2025
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$84MraisedAug 2024 · 16 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Marcos MillaDirector
  • Jay LichterDirector
  • Sergio DuronExecutive Officer, Director
  • Tighe ReardonExecutive Officer
  • James TopperDirector
  • Stephen SquintoDirector
  • Sanford MadiganExecutive Officer
  • Shelley ChuDirector
Offering amount
$110M
Amount sold
$84M
First sale
Apr 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35.3MraisedNov 2022 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sanford MadiganExecutive Officer
  • James TopperDirector
  • Jay LichterDirector
  • Shelley ChuDirector
  • Tighe ReardonExecutive Officer
  • Marcos MillaDirector
  • Sergio DuronExecutive Officer, Director
Offering amount
$61.3M
Amount sold
$35.3M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedOct 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James TopperDirector
  • Sergio DuronExecutive Officer, Director
  • Jay LichterDirector
  • Sanford MadiganExecutive Officer
  • Marcos MillaDirector
  • Shelley ChuDirector
  • Tighe ReardonExecutive Officer
First sale
Sep 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$312KofferedOct 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James TopperDirector
  • Tighe ReardonExecutive Officer
  • Shelley ChuDirector
  • Sergio DuronExecutive Officer, Director
  • Sanford MadiganExecutive Officer
  • Marcos MillaDirector
  • Jay LichterDirector
Offering amount
$312K
First sale
Oct 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedAug 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James TopperDirector
  • Sergio DuronExecutive Officer, Director
  • Marcos MillaDirector
  • Sanford MadiganExecutive Officer
  • Jay LichterDirector
  • Shelley ChuDirector
  • Tighe ReardonExecutive Officer
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedJun 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shelley ChuDirector
  • Tighe ReardonExecutive Officer
  • Sanford MadiganExecutive Officer
  • Sergio DuronExecutive Officer, Director
  • Marcos MillaDirector
  • James TopperDirector
  • Jay LichterDirector
First sale
Jun 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Enlaza Therapeutics Raises $61M in Seed Financingfinsmes.com · Dec 2022

Frequently asked questions

What does Enlaza Therapeutics do?
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.
Who founded Enlaza Therapeutics?
Enlaza Therapeutics was founded by Sergio Duron, Sanford Madigan in 2020.
Who are Enlaza Therapeutics's investors?
Enlaza Therapeutics's investors include Frazier Life Sciences, Lightspeed Venture Partners, Samsara BioCapital, Avalon BioVentures, Pappas Capital, Pfizer Venture Investments, J.P. Morgan Asset Management, OrbiMed.
How much funding has Enlaza Therapeutics raised?
Enlaza Therapeutics has disclosed $134.3M raised across 3 of its 7 known rounds.
Where is Enlaza Therapeutics headquartered?
Enlaza Therapeutics is headquartered in San Diego, US.